Mir-193A-3P Is a Key Tumor Suppressor in Ulcerative Colitis
Total Page:16
File Type:pdf, Size:1020Kb
Published OnlineFirst June 9, 2017; DOI: 10.1158/1078-0432.CCR-17-0171 Biology of Human Tumors Clinical Cancer Research miR-193a-3p is a Key Tumor Suppressor in Ulcerative Colitis–Associated Colon Cancer and Promotes Carcinogenesis through Upregulation of IL17RD Joel Pekow1, Katherine Meckel1, Urszula Dougherty1, Yong Huang1, Xindi Chen1, Anas Almoghrabi1, Reba Mustafi1, Fatma Ayaloglu-Butun1, Zifeng Deng1, Haider I. Haider1, John Hart2, David T. Rubin1, John H. Kwon3, and Marc Bissonnette1 Abstract Purpose: Patients with ulcerative colitis are at increased risk adjacent tissue. Significant down-regulation of miR-193a-3p for colorectal cancer, although mechanisms underlying neo- was also seen in an independent cohort of ulcerative colitis plastic transformation are poorly understood. We sought to cancers. Changes in methylation of miR-193a or expression of evaluate the role of microRNAs in neoplasia development in pri-miR-193a were not observed in ulcerative colitis cancer. this high-risk population. Transfection of miR-193a-3p resulted in decreased prolifera- Experimental Design: Tissue from 12 controls, 9 ulcerative tion, and identified IL17RD as a direct target of miR-193a-3p. colitis patients without neoplasia, and 11 ulcerative colitis IL17RD expression was increased in ulcerative colitis cancers, patients with neoplasia was analyzed. miRNA array analysis was and miR-193a-3p treatment decreased growth and EGFR sig- performed and select miRNAs assayed by real-time PCR on the naling of HCT116 cells in xenografts expressing both IL17RD discovery cohort and a validation cohort. DNA methylation of with WT 30UTR compared with cells expressing IL17RD with miR-193a was assessed. Following transfection of miR-193a-3p, mutant 30UTR. proliferation, IL17RD expression, and luciferase activity of the Conclusions: miR-193a-3p is downregulated in ulcerative 30UTR of IL17RD were measured. Tumor growth in xenografts as colitisneoplasia,anditslosspromotescarcinogenesisthrough well as EGFR signaling were assessed in HCT116 cells expressing upregulation of IL17RD. These findings provide novel insight IL17RD with either a mutant 30 untranslated region (UTR) or into inflammation-driven colorectal cancer and could suggest wild-type (WT) 30UTR. new therapeutic targets in this high-risk population. Clin Cancer Results: miR-31, miR-34a, miR-106b, and miR-193a-3p were Res; 1–11. Ó2017 AACR. significantly dysregulated in ulcerative colitis-neoplasia and Introduction Gene expression is regulated in part by a class of non-coding RNAs, termed microRNAs (miRNA). These small RNAs regulate Patients with long-standing ulcerative colitis are at increased 0 gene expression by binding to the 3 untranslated region (UTR) of risk for colorectal cancer (1, 2). Although many mechanisms of messenger RNA (mRNA) and either inhibit protein translation or carcinogenesis in IBD remain unknown, neoplastic lesions likely destabilize target mRNA (3). Changes in miRNA expression have result from a combination of genetic alterations, inflammatory been implicated in the pathogenesis of many cancer types, mediators, and activation of cell signaling pathways. Discovery of including colon cancer (4–7). miRNAs control the expression of novel genomic mediators of these pathways could greatly facil- signaling molecules and play important roles in cell growth (8). itate risk stratification as well as treatment and chemoprevention As such, growth promoting or cell death inhibiting miRNAs, if strategies. upregulated, could act as gain-of-function oncogenes, whereas growth suppressing or cell death enhancing mRNAs, if down- regulated, could act as loss-of-function tumor suppressors (9). 1University of Chicago, Section of Gastroenterology, Hepatology, and Nutrition, Prior studies, including analyses from our group, indicate that Chicago, Illinois. 2University of Chicago, Department of Pathology, Chicago, fi – 3 the miRNA pro le changes in chronic ulcerative colitis associated Illinois. University of Texas Southwestern, Digestive and Liver Disease Division, inflammation (10–13). Several small studies have also demon- Dallas, Texas. strated dysregulation of multiple miRNAs, including miR-31, Note: Supplementary data for this article are available at Clinical Cancer miR-21, and miR-224, in IBD-associated neoplastic tissue Research Online (http://clincancerres.aacrjournals.org/). (14–17). However, alterations in miRNA expression have not Corresponding Author: Joel Pekow, University of Chicago, KCBD, 900 East 57th been examined globally in a large subset of patients with Street, MB #9, Chicago, IL 60637. Phone: 773-702-7895; Fax: 773-702-2180; advanced ulcerative colitis–associated neoplasia, nor have E-mail: [email protected] miRNA changes been described in non-dysplastic tissue adjacent doi: 10.1158/1078-0432.CCR-17-0171 to a neoplastic lesion. In addition, there has been limited eval- Ó2017 American Association for Cancer Research. uation of the functional role of miRNAs dysregulated in www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst June 9, 2017; DOI: 10.1158/1078-0432.CCR-17-0171 Pekow et al. RNA and DNA extraction Translational Relevance RNA and DNA were extracted from FFPET and fresh-frozen Approximately 1.6 million Americans have inflammatory samples as described in the Supplementary Materials and bowel disease (IBD), which is comprised of Crohn's disease Methods. and ulcerative colitis. Patients with long-standing colonic fl in ammation related to IBD have a high-risk of developing Nanostring analysis colonic neoplasia. Although cancer in IBD differs from spo- miRNA analysis was performed using the Nanostring nCounter radic colon cancer in clinical presentation, progression from expression assay v1 per the manufacturer's specifications. Details dysplasia, and outcome, few studies have mechanistically regarding the analysis of array data are presented in the Supple- examined the pathogenesis of neoplasia in IBD using human mentary Materials and Methods. samples. In this study, we investigated miRNA expression in ulcerative colitis–associated cancer and report that loss of the tumor suppressor, miR-193a-3p, promotes colon carcinogen- Real-time PCR esis in patients with ulcerative colitis. These findings uncover a Quantitative real-time PCR was performed to assess expression novel mechanism of inflammation-associated colon cancer of miR-31, miR-34a, miR-106b, miR-193a-3p, miR-376, miR- IL17RD that has the potential to be used as a target for chemopreven- 497, pri-miR-193a, and as detailed in the Supplementary Materials and Methods. Results were normalized to beta-actin, tion and treatment in this high-risk population. ÀDD comparisons made between groups using the 2 CT method (18), and significance calculated using the Student t test. inflammatory bowel disease (IBD)-carcinogenesis. In this study, Genomic bisulfite sequencing we describe miRNA changes occurring in both IBD-neoplasia as DNA bisulfite treatment was carried out using the Qiagen well as adjacent non-dysplastic tissue and investigate the func- Epitect Bisulfite Kit per the manufacturer's directions. Primers tional role of the tumor suppressor, miR-193a-3p, and a putative for miR-193a designed with methprimer software (L: TTTGAGG- target which potentiates EGFR signaling, interleukin 17 receptor D GATATTTAGAGTTT, R: AACCTAAAAAACAACCTAACC). PCR, (IL17RD), in ulcerative colitis–associated cancer. subcloning of products, and sequencing were carried out as described in the Supplementary Materials and Methods. Analysis Materials and Methods and visualization of CpG dinucleotide methylation were per- formed using BISMA software (http://services.ibc.uni-stuttgart. Tissue de/BDPC/BISMA; ref. 19). Discovery cohort. The study was approved by the institutional review board at the University of Chicago (IRB# 11-0411 and 10- Immunohistochemistry fi fi 209A). Archived formalin- xed paraf n-embedded tissues Immunohistochemistry was carried out as previously described (FFPET) were obtained from normal controls and patients with using antigen retrieval with a citrate buffer and primary antibody ulcerative colitis who underwent a colectomy. Three groups of for IL17RD at a concentration of 1:15 (R & D Systems; ref. 20). patients were examined: Normal controls (N, n ¼ 12), ulcerative colitis patients without neoplasia (ulcerative colitis, n ¼ 9), and ulcerative colitis patients with neoplasia (n ¼ 11). From the Colonocyte Isolation n ¼ ulcerative colitis patients with neoplasia, two separate tissues Colon biopsies ( 6-12/subject) were collected from the þ were analyzed, ulcerative colitis–associated neoplastic tissue sigmoid colon and stored for up to 6 hours at 4 C in transport 2þ 2þ (UCN, n ¼ 10; high-grade dysplasia [HGD]-4, colorectal cancer media which consists of Mg and Ca -free PBS containing 50 m [CRC]-6), and nondysplastic ulcerative colitis tissue adjacent to a IU/mL penicillin, 50 g/mL streptomycin and 0.5 mg/mL genta- neoplastic lesion (nUCaN, n ¼ 10). The tissue adjacent to the mycin. Isolation of colonocyte and stromal fractions was per- neoplastic lesion was obtained from the archived FFPET in closest formed as detailed in the Supplementary Materials and Methods. proximity to the neoplastic lesion. Baseline demographics, site of sample collection, and medication usage for each group is pre- Cell Culture sented in Supplementary Table S1. Additional information on the HCT116, DLD-1, LoVo, and HT29 colon cancer cells,